#Italy #Milan #WuXi Biologics #CPHI Milan #Biologics Sector

WuXi Biologics Showcases Innovations in Biomanufacturing at CPHI Milan 2026

As the demand for advanced therapies rises in Europe, driven by aging populations and an increase in chronic and rare diseases, WuXi Biologics stepped up to showcase its contributions to biomanufacturing at CPHI Milan 2026. This event is pivotal, gathering over 62,000 industry professionals and around 2,900 exhibitors, aimed at fostering collaboration and innovation in the pharmaceutical sector.

Understanding the Growing Biologics Market

The European biologics market, valued at approximately $123.75 billion in 2025, is expected to experience a compound growth rate of 8.1% annually, reaching around $269.65 billion by 2035. This expansion underscores the urgent need for efficient development, robust manufacturing strategies, and a reliable supply chain. WuXi Biologics plays a crucial role in this landscape by integrating advanced technologies to streamline the biomanufacturing process.

WuXi Biologics' Strategic Approach

At CPHI Milan, WuXi Biologics engaged with global biopharmaceutical partners, emphasizing how its innovative technologies can enhance the journey of biologics from development to reliable supply. With increasing complexities in biologics pipelines, companies are keen on partnering with organizations that blend quality with manufacturing excellence, ensuring rapid and steady production. WuXi Biologics addresses this need through its comprehensive Contract Research, Development, and Manufacturing Organization (CRDMO) platform, strategically positioned across Europe.

Emphasizing Quality and Regulatory Excellence

Quality remains at the forefront of WuXi Biologics' operational ethos. By June 2026, the firm had successfully navigated 49 regulatory inspections, including those from the FDA and EMA, and had received over 166 facility license approvals. Clients can trust WuXi's rigorous approach, which includes executing extensive quality audits and maintaining high manufacturing standards across all operations. This foundational track record reassures clients that their products will proceed through development stages consistently and reliably.

Building a Resilient Global Network

A resilient supply chain is critical in today's volatile environment. WuXi Biologics operates an extensive global manufacturing network that spans locations in Ireland, Germany, the United States, China, and Singapore. This interconnected structure enables the company to utilize global quality systems and integrated technology platforms, fostering agility in supply and manufacturing processes. The establishment of Global Dual Sourcing ensures that manufacturers can pivot between sites without sacrificing quality—building a robust, agile supply chain.

Enhancing European Manufacturing Capabilities

The significance of having established regional manufacturing sites in Europe cannot be overstated. WuXi Biologics boasts operational sites in Dundalk, Ireland, and Wuppertal, Germany, which enhance production capabilities and bring services closer to key markets. The Dundalk site is recognized as a commercial manufacturing hub, operating under strict GMP guidelines and currently managing multiple large-scale projects. Moreover, the recognition received for operational excellence speaks volumes about the site's reliability and efficiency.

Dundalk: A Hub of Operations

With a capacity of 54,000 liters for drug substance manufacturing, Dundalk is performing crucial roles in supporting EMA-approved products. This site has proven adept at executing scale-up and technology transfer projects while upholding strict quality standards, thereby ensuring consistency across the board. Acknowledged as a leader in the pharmaceutical manufacturing sector, Dundalk received the ISPE Facility of the Year Award in 2023 and continues to be a pivotal component of WuXi's European strategy.

Wuppertal: Committed to Flexibility

Complementing Dundalk, the Wuppertal site offers adaptable manufacturing solutions at various scales. This facility supports drug development stages efficiently, leveraging advanced quality-control laboratories and warehousing capabilities. Wuppertal is positioned strategically in North Rhine-Westphalia, enhancing access to a key life-sciences region in Europe.

Innovation and Speed in Manufacturing

WuXi Biologics is committed to accelerating the drug development process. With a comprehensive CRDMO platform, the company supports diverse projects, from bispecific antibodies to complex modalities. This format has proven to be effective, facilitating project transitions from development to commercial scale, often within a remarkably short timeframe.

Technologies Driving Fast-Track Development

WuXia™ TrueSite, the company’s advanced cell-line platform, and WuXiHigh™ 2.0 for high-dose delivery are key innovations designed to streamline processes. By offering predictable stability and enhanced delivery methods, these technologies ensure that timelines are not only met but also de-risked significantly. The goal of WuXi is clear: to blend speed, quality, and precision in every project phase while maintaining compliance and reliability.

Conclusion: The Future of Biomanufacturing with WuXi

As the biomanufacturing landscape evolves, WuXi Biologics stands out as a beacon of quality, innovation, and resiliency. The future hinges not only on capacity but also on the ability to adapt, innovate, and deliver with confidence. Through their robust European operations and global presence, WuXi Biologics is tailored to meet the burgeoning demands of advanced biotherapeutics, paving the way for meaningful progress in patient care worldwide.